Juluca

Dolutegravir Sodium and Rilpivirine Hydrochloride, the active ingredient in Juluca, is an integrase strand transfer inhibitor and non‑nucleoside reverse transcriptase inhibitor presented as a 50 mg/25 mg film‑coated tablet for oral use. It treats HIV‑1 infection as a maintenance therapy in virologically suppressed adults.

GNH USA supplies Juluca as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, ensuring quality and regulatory compliance across markets.

Juluca is indicated for HIV‑1 infection as part of antiretroviral therapy in virologically suppressed adults.

- Maintenance therapy for HIV‑1 infection: provides continued viral suppression in adults who are already virologically suppressed. - Switching from current antiretroviral regimen: enables transition to a single‑tablet regimen while maintaining viral control. - HIV‑1 infected adults without resistance to integrase inhibitors or NNRTIs: suitable as a complete regimen for patients meeting resistance criteria.

Juluca may cause a range of adverse reactions. Patients should be monitored for any new symptoms.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional, may improve with food. - Diarrhea: watery stools, usually transient. - Insomnia: difficulty falling or staying asleep. - Fatigue: generalized tiredness. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Hepatic failure: signs include jaundice, dark urine, and abdominal pain. - Severe depression or suicidal ideation: mood changes requiring immediate evaluation. - Hypersensitivity reactions: including angioedema or anaphylaxis. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin blistering. - Elevated serum creatinine: indicating possible renal impact. - QT interval prolongation: may predispose to cardiac arrhythmias.

Before initiating Juluca, clinicians should assess patient history and monitor relevant parameters.

- Resistance testing: ensure no prior resistance to integrase inhibitors or NNRTIs. - Liver function: evaluate hepatic enzymes in patients with existing liver disease. - Psychiatric assessment: screen for depression or suicidal thoughts. - Drug interactions: review concomitant medications for potential interactions. - Pregnancy and breastfeeding: weigh benefits against unknown risks. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Juluca can interact with several drug classes; careful review is essential.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce rilpivirine absorption. - Rifampicin or other strong enzyme inducers: markedly lower dolutegravir levels. - Carbamazepine, phenytoin, or phenobarbital: may decrease efficacy of both components.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect rilpivirine exposure; consider timing adjustments. - St. John’s wort: can reduce dolutegravir concentrations. - Certain antidiabetic agents: monitor blood glucose as rilpivirine may affect metabolism.